Shaw G K, Waller S, Majumdar S K, Alberts J L, Latham C J, Dunn G
Bexley Hospital, Kent.
Br J Psychiatry. 1994 Oct;165(4):515-23. doi: 10.1192/bjp.165.4.515.
The aim was to investigate the effect of tiapride (100 mg three times a day for at least one month) on outcome following detoxification.
The setting was a tertiary referral centre. The study design was randomised, double-blind, and placebo-controlled. One hundred routinely admitted alcohol-dependent patients were entered, and 54 completed the trial. Outcome was assessed by considering drinking status at three months and six months follow-up, and by comparing psychological status at intake and follow-up using the Crown-Crisp Experiential index, the Litman Self-esteem scale and a Satisfaction with Life Situations scale. We also compared performance over the six months before admission with the three and six months of follow-up on measures of health, social and drinking variables.
Tiapride proved better (usually at statistically highly significant levels) than placebo at promoting: abstinence, self-esteem, and satisfaction with life situations; and at reducing: alcohol consumption, use of health service resources, and levels of neuroticism.
Tiapride merits serious consideration in the longer-term treatment of alcoholic patients.
目的是研究硫必利（每日三次，每次100毫克，至少服用一个月）对脱毒后疗效的影响。
研究地点为三级转诊中心。研究设计为随机、双盲、安慰剂对照。纳入100例常规收治的酒精依赖患者，54例完成试验。通过考虑三个月和六个月随访时的饮酒状况，以及使用克朗-克里斯普体验指数、利特曼自尊量表和生活状况满意度量表比较入组时和随访时的心理状况来评估疗效。我们还比较了入院前六个月与随访三个月和六个月期间在健康、社会和饮酒变量方面的表现。
在促进戒酒、自尊和生活状况满意度，以及减少酒精消费、医疗服务资源使用和神经质水平方面，硫必利比安慰剂效果更好（通常在统计学上具有高度显著性）。
在酒精依赖患者的长期治疗中，硫必利值得认真考虑。
